Friday, July 10, 2026

pharma · Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) · Advanced Solid Tumor

Daiichi Sankyo US

Daiichi Sankyo US clinical programs — 58 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US HQ
4,386 Employees
NMPA registrant Type
Company details
Status
Public
HQ
211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US
Employees
4,386
Programs
58
Drugs
66
Patents
0
Intelligence · Clinical Programs

Daiichi Sankyo US projects

58 ClinicalTrials.gov programs sponsored by Daiichi Sankyo US.

Daiichi Sankyo US has 58 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

Page 2 of 2
  1. DSE-BMP-0004-CIS-MA

    Daiichi Sankyo

    No medical condition.

    phase 1 other active

    1 trial
  2. First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors

    Daiichi Sankyo

    Advanced Solid Tumors

    phase 1 other active

    1 trial
  3. First-in-Human trial of DS9051b in participants with advanced solid tumors

    Daiichi Sankyo

    Advanced or Metastatic Adrenocortical Carcinoma (ACC), Metastatic Castration-resistant Prostate Cancer (CRPC)

    phase 1 other active

    1 trial
  4. First-in-human (FIH) Study of DS-1471a in Subjects with Advanced Solid Tumors

    Daiichi Sankyo

    Advanced Solid Tumors

    phase 1 other active

    1 trial
  5. First-in-human Trial of DS-2243a in Participants with Advanced Solid Tumors

    Daiichi Sankyo

    Advanced Solid Tumor

    phase 1 other active

    1 trial
  6. HER3-DXd

    Daiichi Sankyo

    Non-Small Cell Lung Cancer (NSCLC)

    phase 1 small molecule active

    1 trial
  7. Phase 1 trial of valemetostat and darolutamide in mCRPC

    Daiichi Sankyo

    Metastatic Castration Resistant Prostate Cancer (mCRPC)

    phase 1 other active

    1 trial
  8. Study of U3-1402 in subjects with non-small cell lung cancer

    Daiichi Sankyo

    METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER

    phase 1 other active

    1 trial
  9. Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.

    Daiichi Sankyo

    Advanced Solid Tumor

    phase 1 other active

    1 trial
  10. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Recurrent or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Daiichi Sankyo US have?

58 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.